Bendamustine and subcutaneous rituximab
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Aggressive Lymphoma
Conditions
Aggressive Lymphoma
Trial Timeline
Jul 4, 2012 → Aug 8, 2018
NCT ID
NCT01686321About Bendamustine and subcutaneous rituximab
Bendamustine and subcutaneous rituximab is a phase 2 stage product being developed by Roche for Aggressive Lymphoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01686321. Target conditions include Aggressive Lymphoma.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01686321 | Phase 2 | Completed |
Competing Products
11 competing products in Aggressive Lymphoma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ACALABRUTINIB + LISOCABTAGENE MARALEUCEL + Lymphodepleting chemotherapy | Johnson & Johnson | Phase 2 | 52 |
| Loncastuximab Tesirine and Epcoritamab | AbbVie | Phase 2 | 52 |
| Cabazitaxel + Carboplatin + Prednisone 5Mg + Olaparib | AstraZeneca | Phase 2 | 52 |
| Midostaurin | Novartis | Phase 2 | 52 |
| Imatinib | Novartis | Phase 2 | 52 |
| Cyclophosphamide + Doxorubicin Hydrochloride + Nivolumab + Prednisone + Rituximab + Vincristine Sulfate | Bristol Myers Squibb | Phase 1/2 | 40 |
| Cyclophosphamide + Doxorubicin Hydrochloride + Etoposide + Nivolumab + Prednisone + Rituximab + Vincristine Sulfate | Bristol Myers Squibb | Phase 2 | 51 |
| Vandetanib 300 mg | Sanofi | Pre-clinical | 22 |
| cemiplimab + odronextamab | Regeneron Pharmaceuticals | Phase 1 | 32 |
| Zanzalintinib | Exelixis | Phase 2 | 49 |
| PRT2527 + Zanubrutinib + Venetoclax | Prelude Therapeutics | Phase 1 | 25 |